Abstract
At times, technologies fail for reasons other than an inability to deliver on their promises. The iconic Blackberry, for example, was once coined “Research in Motion”, sold tens of millions of units, and then “disappeared” from the market because it did not accompany the new trends in design. Promising technologies may also “disappear” in the medical field. What follows is the tale of the rise and fall of proton magnetic resonance spectroscopic imaging (1H MRSI) of the prostate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cornel EB, Smits GA, Oosterhof GO, Karthaus HF, Deburyne FM, Schalken JA, et al. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol. 1993;150:2019-24.
Kurhanewicz J, Dahiya R, Macdonald JM, Chang LH, James TL, Narayan P. Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med. 1993;29:149-57.
Fowler AH, Pappas AA, Holder JC, Finkbeiner AE, Dalrymple GV, Mullins MS, et al. Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR. Magn Reson Med. 1992;25:140-7.
Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995;45:459-66.
Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997;17:1455-60.
Mazaheri Y, Shukla-Dave A, Goldman DA, Moskowitz CS, Takeda T, Reuter VE, et al. Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3Tesla. Magn Reson Imaging. 2019;55:93-102.
Leapman MS, Wang ZJ, Behr SC, Kurhanewicz J, Zagoria RJ, Carroll PR, et al. Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer. Radiol Bras. 2017;50:299-307.
Fusco R, Sansone M, Petrillo M, Setola SV, Granata V, Botti G, et al. Multiparametric MRI for prostate cancer detection: Preliminary results on quantitative analysis of dynamic contrast enhanced imaging, diffusion-weighted imaging and spectroscopy imaging. Magn Reson Imaging. 2016;34:839-45.
Lagemaat MW, Zechmann CM, Futterer JJ, Weiland E, Lu J, Villeirs GM, et al. Reproducibility of 3D 1H MR spectroscopic imaging of the prostate at 1.5T. J Magn Reson Imaging. 2012;35:166-73.
Gibbs P, Tozer DJ, Liney GP, Turnbull LW. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46:1054-8.
Gibbs P, Tozer DJ, Liney GP, Turnbull LW. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46:1054-8.
Song SK, Qu Z, Garabedian EM, Gordon JI, Milbrandt J, Ackerman JJ. Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res. 2002;62:1555-8.
Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746-57.
Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69:16-40.
Spilseth B, Margolis DJ, Ghai S, Patel NU, Rosenkrantz AB. Radiologists’ preferences regarding content of prostate MRI reports: a survey of the Society of Abdominal Radiology. Abdominal radiology. 2018;43:1807-12.
Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016;196:1613-8.
Bellomo G, Marcocci F, Bianchini D, Mezzenga E, D’Errico V, Menghi E, et al. MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification. PLoS One. 2016;11:e0165730.
Starobinets O, Simko JP, Kuchinsky K, Kornak J, Carroll PR, Greene KL, et al. Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard. NMR Biomed. 2017;30.
Steinseifer IK, van Asten JJ, Weiland E, Scheenen TW, Maas MC, Heerschap A. Improved volume selective (1) H MR spectroscopic imaging of the prostate with gradient offset independent adiabaticity pulses at 3 tesla. Magn Reson Med. 2015;74:915-24.
Tayari N, Steinseifer IK, Selnaes KM, Bathen TF, Maas MC, Heerschap A. High-Quality 3-Dimensional 1H Magnetic Resonance Spectroscopic Imaging of the Prostate Without Endorectal Receive Coil Using A Semi-LASER Sequence. Invest Radiol. 2017;52:640-6.
Smith CP, Harmon SA, Barrett T, Bittencourt LK, Law YM, Shebel H, et al. Intra- and interreader reproducibility of PI-RADSv2: A multireader study. J Magn Reson Imaging. 2019;49:1694-703.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Westphalen, A.C. Lost in translation: lessons learned from the “demise” of MRSI of the prostate. Abdom Radiol 44, 3185–3187 (2019). https://doi.org/10.1007/s00261-019-02114-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-019-02114-z